BR112022016448A2 - Método para tratamento de doença do enxerto contra hospedeiro crônica - Google Patents

Método para tratamento de doença do enxerto contra hospedeiro crônica

Info

Publication number
BR112022016448A2
BR112022016448A2 BR112022016448A BR112022016448A BR112022016448A2 BR 112022016448 A2 BR112022016448 A2 BR 112022016448A2 BR 112022016448 A BR112022016448 A BR 112022016448A BR 112022016448 A BR112022016448 A BR 112022016448A BR 112022016448 A2 BR112022016448 A2 BR 112022016448A2
Authority
BR
Brazil
Prior art keywords
host disease
chronic graft
treatment
individual
versus host
Prior art date
Application number
BR112022016448A
Other languages
English (en)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022016448A2 publication Critical patent/BR112022016448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA TRATAMENTO DE DOENÇA DO ENXERTO CONTRA HOSPEDEIRO CRÔNICA. A presente descrição se refere a métodos para tratar ou prevenir Doença do Enxerto contra Hospedeiro Crônica em um indivíduo em necessidade do mesmo, o método compreendendo administrar ao indivíduo uma composição compreendendo células precursoras ou tronco de linhagem mesenquimal expandida de cultura (MLPSCs).
BR112022016448A 2020-02-19 2021-02-18 Método para tratamento de doença do enxerto contra hospedeiro crônica BR112022016448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (1)

Publication Number Publication Date
BR112022016448A2 true BR112022016448A2 (pt) 2022-11-29

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016448A BR112022016448A2 (pt) 2020-02-19 2021-02-18 Método para tratamento de doença do enxerto contra hospedeiro crônica

Country Status (9)

Country Link
US (1) US20230097931A1 (pt)
EP (1) EP4106776A1 (pt)
JP (1) JP2023513847A (pt)
KR (1) KR20220143092A (pt)
CN (1) CN115361960A (pt)
AU (1) AU2021222342A1 (pt)
BR (1) BR112022016448A2 (pt)
CA (1) CA3168330A1 (pt)
WO (1) WO2021165420A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008774A (es) 2006-01-13 2008-09-26 Osiris Therapeutics Inc Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
WO2015061839A1 (en) * 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
KR102660506B1 (ko) * 2017-05-04 2024-04-25 메조블라스트 인터내셔널 에스에이알엘 면역억제가 향상된 간충직 계통 전구체 또는 줄기 세포

Also Published As

Publication number Publication date
KR20220143092A (ko) 2022-10-24
EP4106776A1 (en) 2022-12-28
CA3168330A1 (en) 2021-08-26
JP2023513847A (ja) 2023-04-03
US20230097931A1 (en) 2023-03-30
WO2021165420A1 (en) 2021-08-26
AU2021222342A1 (en) 2022-09-15
CN115361960A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
AR113011A1 (es) Vesículas extracelulares bacterianas
MX2021012391A (es) Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos.
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112019022901A2 (pt) precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
BR112015021453A8 (pt) método de tratamento de condições do pâncreas e do fígado pelo transplante de células-tronco nas paredes do duto biliar
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112017019189A8 (pt) Agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
BR112022024420A2 (pt) Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
BR112022008700A2 (pt) Método para tratar ou prevenir uma doença falciforme, e, transplante de células hematopoiéticas imaturas e uma quantidade terapeuticamente eficaz de uma população isolada de células anti-terceiros não indutoras de doença do enxerto versus hospedeiro
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
BR112017023660A2 (pt) ensaio de potência
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112017024065A2 (pt) método para tratar insuficiência cardíaca avançada em um indivíduo humano
BR112023001049A2 (pt) Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética
WO2018220444A3 (en) COMPOSITIONS AND METHODS FOR TREATING DRY KERNATOCONJUNCTIVITIS SYNDROME BY ADMINISTERING A MACROLIDE ANTIBIOTIC
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
WO2020061067A3 (en) Compositions and methods for treating bone injury
BR112023021825A2 (pt) Método para tratar síndrome da angústia respiratória aguda (sara) em pacientes específicos utilizando precursores de linhagem mesenquimal ou células tronco
AR121013A1 (es) Anticuerpos anti-cd40 y composiciones
MX2021013612A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.